This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hohmann, F. P. Articles by Fauser, B. C. J. M. Search for Related Content PubMed PubMed Citation Articles by Hohmann, F. P. Articles by Fauser, B. C. J. M.

A Randomized Comparison of Two Ovarian Stimulation Protocols with Gonadotropin-Releasing Hormone (GnRH) Antagonist Cotreatment for in Vitro Fertilization Commencing Recombinant Follicle-Stimulating Hormone on Cycle Day 2 or 5 with the Standard Long GnRH Agonist Protocol

Division of Reproductive Medicine, Department of Obstetrics and Gynecology (F.P.H., N.S.M., B.C.J.M.F.), Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands

Address all correspondence and requests for reprints to: Prof. B. C. J. M. Fauser, M.D., Ph.D., Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. E-mail: fauser{at}gyna.azr.nl.

Extending the FSH window for multifollicular development by administering FSH from the midfollicular phase onward constitutes a novel mild protocol for ovarian stimulation for in vitro fertilization (IVF) based on the physiology of single dominant follicle selection in normo-ovulatory women. We compared outcomes from this protocol with two other stimulation protocols. One hundred and forty-two normo-ovulatory patients with an indication for IVF (or IVF/ICSI) were randomized to a GnRH agonist long protocol (group A; n = 45) or one of two GnRH antagonist protocols commencing recombinant FSH on cycle d 2 (group B; n = 48) or cycle d 5 (group C; n = 49). A fixed dose (150 IU/d) of rFSH was used for ovarian stimulation, and GnRH antagonist cotreatment was initiated on the day when the leading follicle reached 14 mm diameter.

Group C showed a shorter duration of stimulation (median duration, 11, 9, and 8 d for groups A, B, and C, respectively; P < 0.001), reflected in a significantly lower total dose of rFSH used (median amount of rFSH, 1650, 1350, and 1200 IU for groups A, B, and C, respectively; P < 0.001). In group C more cycles were cancelled during the stimulation phase due to insufficient response, resulting in a lower percentage of oocyte retrievals (84%, 73%, and 63% for groups A, B, and C; P = 0.02). However, women in group C obtained better quality embryos (percentage of embryo score of 1 for best embryo, 29%, 37%, and 61% for groups A, B, and C, respectively; P = 0.008), resulting in more transfers per oocyte retrieval (68%, 71%, and 90% for groups A, B, and C, respectively; P = 0.04). After profound ovarian stimulation (groups A and B) only 7% of the patients who retrieved four oocytes or less conceived, whereas after mild stimulation (group C) 67% of these patients conceived (P < 0.01). Overall, no differences were found among the three groups comparing pregnancy rate per started IVF cycle.

In conclusion, application of the described mild ovarian stimulation protocol resulted in pregnancy rates per started IVF cycle similar to those observed after profound stimulation with GnRH agonist cotreatment despite shorter stimulation and a 27% reduction in exogenous FSH. A higher cancellation rate before oocyte retrieval was compensated by improved embryo quality concomitant with a higher chance of undergoing embryo transfer. A relatively low number of oocytes retrieved after mild ovarian stimulation distinctly differs from the pathological reduction in the number of oocytes retrieved after profound ovarian stimulation (poor response) associated with poor IVF outcome. The relatively small number of oocytes obtained after mild ovarian stimulation may represent the best of the cohort in a given cycle.

This work was supported by the Stichting Voortplantingsgeneeskunde Rotterdam and an unrestricted research grant from ASTA Medica B.V. (Amsterdam, The Netherlands).

Abbreviations: E2, Estradiol; ET, embryo transfer; hCG, human chorionic gonadotropin; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; P, progesterone; rFSH, recombinant FSH; TVS, transvaginal sonography.

This article has been cited by other articles:

				W. Ombelet, I. Cooke, S. Dyer, G. Serour, and P. Devroey Infertility and the provision of infertility medical services in developing countries Hum. Reprod. Update, September 26, 2008; (2008) dmn042v1. [Abstract] [Full Text] [PDF]

				The Corifollitropin Alfa Dose-finding Study Group A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation Hum. Reprod., August 6, 2008; (2008) den288v1. [Abstract] [Full Text] [PDF]

				G. Griesinger, E.M. Kolibianakis, K. Diedrich, and M. Ludwig Ovarian stimulation for IVF has no quantitative association with birthweight: a registry study Hum. Reprod., August 6, 2008; (2008) den286v1. [Abstract] [Full Text] [PDF]

				S. Lie Fong, P.J. Lugtenburg, I. Schipper, A.P.N. Themmen, F.H. de Jong, P. Sonneveld, and J.S.E. Laven Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies Hum. Reprod., March 1, 2008; 23(3): 674 - 678. [Abstract] [Full Text] [PDF]

				S. Polinder, E.M.E.W. Heijnen, N.S. Macklon, J.D.F. Habbema, B.J.C.M. Fauser, and M.J.C. Eijkemans Cost-effectiveness of a mild compared with a standard strategy for IVF: a randomized comparison using cumulative term live birth as the primary endpoint Hum. Reprod., February 1, 2008; 23(2): 316 - 323. [Abstract] [Full Text] [PDF]

				C. de Klerk, J.A.M. Hunfeld, E.M.E.W. Heijnen, M.J.C. Eijkemans, B.C.J.M. Fauser, J. Passchier, and N.S. Macklon Low negative affect prior to treatment is associated with a decreased chance of live birth from a first IVF cycle Hum. Reprod., January 1, 2008; 23(1): 112 - 116. [Abstract] [Full Text] [PDF]

				The ESHRE Capri Workshop Group Intracytoplasmic sperm injection (ICSI) in 2006: Evidence and Evolution Hum. Reprod. Update, November 1, 2007; 13(6): 515 - 526. [Abstract] [Full Text] [PDF]

				J.A. Huirne, R. Homburg, and C.B. Lambalk Are GnRH antagonists comparable to agonists for use in IVF? Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813. [Abstract] [Full Text] [PDF]

				C. de Klerk, N.S. Macklon, E.M.E.W. Heijnen, M.J.C. Eijkemans, B.C.J.M. Fauser, J. Passchier, and J.A.M. Hunfeld The psychological impact of IVF failure after two or more cycles of IVF with a mild versus standard treatment strategy Hum. Reprod., September 1, 2007; 22(9): 2554 - 2558. [Abstract] [Full Text] [PDF]

				K. Diedrich, B.C.J.M. Fauser, P. Devroey, G. Griesinger, and on behalf of the Evian Annual Reproduction (EVAR) The role of the endometrium and embryo in human implantation Hum. Reprod. Update, July 1, 2007; 13(4): 365 - 377. [Abstract] [Full Text] [PDF]

				M.F.G. Verberg, M.J.C. Eijkemans, N.S. Macklon, E.M.E.W. Heijnen, B.C.J.M. Fauser, and F.J. Broekmans Predictors of low response to mild ovarian stimulation initiated on cycle day 5 for IVF Hum. Reprod., July 1, 2007; 22(7): 1919 - 1924. [Abstract] [Full Text] [PDF]

				E. B. Baart, E. Martini, M. J. Eijkemans, D. Van Opstal, N. G.M. Beckers, A. Verhoeff, N. S. Macklon, and B. C.J.M. Fauser Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial Hum. Reprod., April 1, 2007; 22(4): 980 - 988. [Abstract] [Full Text] [PDF]

				E.M. Kolibianakis, J. Collins, B.C. Tarlatzis, P. Devroey, K. Diedrich, and G. Griesinger Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis Hum. Reprod. Update, November 1, 2006; 12(6): 651 - 671. [Abstract] [Full Text] [PDF]

				B.C. Tarlatzis, B.C. Fauser, E.M. Kolibianakis, K. Diedrich, P. Devroey, and , On Behalf of the Brussels GnRH Antagonist Consen GnRH antagonists in ovarian stimulation for IVF Hum. Reprod. Update, July 1, 2006; 12(4): 333 - 340. [Abstract] [Full Text] [PDF]

				N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]

				C. de Klerk, E.M.E.W. Heijnen, N.S. Macklon, H.J. Duivenvoorden, B.C.J.M. Fauser, J. Passchier, and J.A.M. Hunfeld The psychological impact of mild ovarian stimulation combined with single embryo transfer compared with conventional IVF Hum. Reprod., March 1, 2006; 21(3): 721 - 727. [Abstract] [Full Text] [PDF]

				M.J.C. Eijkemans, E.M.E.W. Heijnen, C. de Klerk, J.D.F. Habbema, and B.C.J.M. Fauser Comparison of different treatment strategies in IVF with cumulative live birth over a given period of time as the primary end-point: methodological considerations on a randomized controlled non-inferiority trial Hum. Reprod., February 1, 2006; 21(2): 344 - 351. [Abstract] [Full Text] [PDF]

				L. Rombauts, D. Healy, R. J. Norman, and on behalf of the Orgalutran Scheduling Study Group A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients Hum. Reprod., January 1, 2006; 21(1): 95 - 103. [Abstract] [Full Text] [PDF]

				E.B. Baart, E. Martini, I. van den Berg, N.S. Macklon, R-J.H. Galjaard, B.C.J.M. Fauser, and D. Van Opstal Preimplantation genetic screening reveals a high incidence of aneuploidy and mosaicism in embryos from young women undergoing IVF Hum. Reprod., January 1, 2006; 21(1): 223 - 233. [Abstract] [Full Text] [PDF]

				E.M.E.W. Heijnen, N.S. Macklon, and B.C.J.M. Fauser What is the most relevant standard of success in assisted reproduction?: The next step to improving outcomes of IVF: consider the whole treatment Hum. Reprod., September 1, 2004; 19(9): 1936 - 1938. [Abstract] [Full Text] [PDF]

				P. Devroey, B. C. Fauser, P. Platteau, N. G. Beckers, M. Dhont, and B. M. Mannaerts Induction of Multiple Follicular Development by a Single Dose of Long-Acting Recombinant Follicle-Stimulating Hormone (FSH-CTP, Corifollitropin Alfa) for Controlled Ovarian Stimulation before in Vitro Fertilization J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2062 - 2070. [Abstract] [Full Text] [PDF]

				E.B. Baart, D. Van Opstal, F.J. Los, B.C.J.M. Fauser, and E. Martini Fluorescence in situ hybridization analysis of two blastomeres from day 3 frozen-thawed embryos followed by analysis of the remaining embryo on day 5 Hum. Reprod., March 1, 2004; 19(3): 685 - 693. [Abstract] [Full Text] [PDF]

				N. G. M. Beckers, N. S. Macklon, M. J. Eijkemans, M. Ludwig, R. E. Felberbaum, K. Diedrich, S. Bustion, E. Loumaye, and B. C. J. M. Fauser Nonsupplemented Luteal Phase Characteristics after the Administration of Recombinant Human Chorionic Gonadotropin, Recombinant Luteinizing Hormone, or Gonadotropin-Releasing Hormone (GnRH) Agonist to Induce Final Oocyte Maturation in in Vitro Fertilization Patients after Ovarian Stimulation with Recombinant Follicle-Stimulating Hormone and GnRH Antagonist Cotreatment J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4186 - 4192. [Abstract] [Full Text] [PDF]

				F. J. Broekmans, S. M. Weima, and E. R. te Velde A Randomized Comparison of Two Ovarian Stimulation Protocols with Gonadotropin-Releasing Hormone (GnRH) Antagonist Cotreatment for in Vitro Fertilization Commencing Recombinant Follicle-Stimulating Hormone on Cycle Day 2 or 5 with the Standard Long GnRH Agonist Protocol J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4510 - 4510. [Full Text]

				B. C. J. M. Fauser and N. S. Macklon Authors' Response: A Randomized Comparison of Two Ovarian Stimulation Protocols with Gonadotropin-Releasing Hormone (GnRH) Antagonist Cotreatment for in Vitro Fertilization Commencing Recombinant Follicle-Stimulating Hormone on Cycle Day 2 or 5 with the Standard Long GnRH Agonist Protocol J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4510 - 4511. [Full Text]